CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a significant improvement in financial performance, with a shift from operating losses to profits, and strong revenue growth due to a new partnership with GSK. Despite a slight EPS miss, the cash position is strong, and the company is strategically focusing on oncology. The Q&A section reveals cautious optimism in clinical trials and regulatory interactions, with no major negative surprises. Overall, the financial health and strategic focus on partnerships suggest a positive market reaction.
Key Financial Performance
EPS Reported EPS is $-0.16564, compared to expectations of $-0.14.
Cash Position Cash position of EUR481.7 million at the end of 2024, increased from EUR402.5 million at the end of 2023, primarily due to a EUR400 million upfront payment from GSK.
Revenue (Q4 2024) Revenue decreased by EUR8.1 million to EUR14.5 million for the fourth quarter of 2024, driven by lower ongoing R&D activities.
Revenue (Full Year 2024) Revenue increased by EUR481.4 million to EUR535.2 million for the full year of 2024, primarily driven by the new licensing agreement with GSK.
Operating Loss (Q4 2024) Operating loss was EUR43.8 million for Q4 2024, compared to an operating loss of EUR88 million for Q4 2023.
Operating Profit (Full Year 2024) Operating profit was EUR177.7 million for the full year 2024, compared to an operating loss of EUR274.2 million for the same period in 2023.
R&D Expenses R&D expenses increased due to strategic changes, with higher investments in oncology development programs and increased litigation expenses.
General and Administrative Expenses General and administrative expenses decreased compared to the prior year, mainly driven by lower personnel expenses.
Financial Results (Q4 2024) Financial results increased by EUR3.7 million to EUR5.2 million in Q4 2024.
Financial Results (Full Year 2024) Financial results decreased by EUR1 million to EUR13.2 million for the full year 2024, mainly driven by lower interest income on cash investments.
Pretax Loss (Q4 2024) Pretax loss was EUR38.6 million for Q4 2024.
Pretax Profit (Full Year 2024) Pretax profit was EUR190.9 million for the full year 2024, compared to pretax losses in the same periods of 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Oncology Pipeline: CureVac's lead program in patients with resected glioblastoma has completed enrollment of Part B in its Phase 1 study, with promising dose escalation data indicating acceptable tolerability and antigen-specific T-cell responses.
Squamous Non-Small Cell Lung Cancer Program: CureVac's off-the-shelf precision immunotherapy program for squamous non-small cell lung cancer received IND clearance from the FDA, with the first patient expected to be treated in the second half of 2025.
UPEC Vaccine Program: CureVac initiated a program for a prophylactic vaccine against uropathogenic E. coli bacteria, targeting urinary tract infections, with an IND submission expected in the second half of 2025.
Licensing Agreement with GSK: CureVac signed a licensing agreement with GSK valued up to EUR1.45 billion, which includes a EUR400 million upfront payment and potential milestone payments.
GSK Seasonal Influenza Vaccine: GSK's clinical program for a seasonal influenza vaccine, based on CureVac's mRNA technology, is preparing for Phase 3, which will trigger another significant milestone payment.
Workforce Reduction: CureVac completed a 30% workforce reduction in 2024 to streamline operations and enhance efficiency.
Cash Position: CureVac closed 2024 with a strong cash position of EUR482 million, providing a financial runway into 2028.
Corporate Restructuring: CureVac undertook a strategic corporate restructuring to focus on technology innovation and R&D, enhancing operational efficiency.
IP Portfolio Defense: CureVac is actively defending its broad IP portfolio, with key decisions anticipated in Europe and the US throughout 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Miss: CureVac reported an EPS of $-0.16564, missing expectations of $-0.14, indicating potential financial instability.
Regulatory Challenges: The company is involved in ongoing litigation regarding intellectual property rights, particularly with Pfizer-BioNTech, which could impact future revenues and operational focus.
Supply Chain and Manufacturing Issues: CureVac has streamlined operations, including a 30% workforce reduction and impairment of large-scale production facilities, which may affect their ability to scale production for future products.
Market Competition: CureVac faces significant competition in the mRNA space, particularly from established players like Pfizer-BioNTech, which could hinder market share and revenue growth.
Economic Factors: The company’s financial results were impacted by extraordinary payments related to their first-generation COVID-19 vaccine, totaling EUR137 million, which could affect future financial stability.
R&D Investment Risks: Increased R&D expenses due to strategic changes and ongoing litigation may strain financial resources, impacting the ability to fund future projects.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Restructuring: CureVac undertook a strategic corporate restructuring, including a 30% workforce reduction, to enhance operational efficiency and focus on R&D priorities.
Licensing Agreement with GSK: CureVac signed a licensing agreement with GSK valued up to EUR1.45 billion, which includes a EUR400 million upfront payment and potential milestone payments.
Pipeline Expansion: CureVac is advancing its oncology and infectious disease pipelines, including programs for glioblastoma and squamous non-small cell lung cancer.
Intellectual Property Validation: The European Patent Office upheld the validity of CureVac's split poly-A tail patent, reinforcing its position in mRNA technology.
Cash Position: CureVac closed 2024 with a strong cash position of EUR482 million, providing a financial runway into 2028.
Revenue Expectations: CureVac anticipates a substantial decrease in operating expenses by over 30% in 2025, including a EUR25 million reduction in personnel costs.
Clinical Milestones: CureVac expects to share data from the Phase 1 glioblastoma study in the second half of 2025 and to treat the first patient in the squamous non-small cell lung cancer program in the second half of 2025.
IND Submissions: CureVac plans to file an IND for the UPEC vaccine in the second half of 2025, with Phase 1 clinical development expected to start in the first half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Position: CureVac closed 2024 with a strong cash position of EUR482 million, reaffirming their expected financial runway into 2028.
Licensing Agreement with GSK: CureVac entered a licensing agreement with GSK valued up to EUR1.45 billion, which includes a EUR400 million upfront payment.
Milestone Payments: A development milestone of EUR10 million was reached under the new license agreement for the initiation of a Phase 1 for a combo vaccine.
Cost Reductions: CureVac anticipates a substantial decrease in operating expenses by over 30%, including a notable EUR25 million reduction in personnel costs.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the early signs you point to in the first-in-human clinical readout as evidence that including these antigens is having a preferential effect on activity?
A:We have an antigen discovery platform that runs extensive validation assays to ensure the selected antigens are expressed on tumors, not on healthy tissue, and can be recognized by immune cells. Preclinical evidence suggests strong immune responses to these novel antigens, but there is currently no clinical evidence as this is the first time testing them in cancer patients.
Q:Will the first patient dose in the second half of this year set you up for a mid or second half ’26 readout from the Phase 1?
A:We want to be cautious as this is a first-in-human study with dose escalation. We do not feel comfortable sharing projections at this time, but we will provide updates as recruitment progresses.
Q:What is the regulatory path for the CVGBM asset? Have you had conversations with regulators?
A:We have not seen any negative impact from the FDA on our programs so far. For CVGBM, if Phase 1 data shows meaningful clinical activity, we would consider a Phase 2 with a randomized design.
Q:What is the criteria to make go/no-go decisions for GBM?
A:We expect to see an overall survival of 50 months or longer and an overall response rate of about 20% to consider moving forward.
Q:Can you provide more detail on the cash runway guidance into 2028?
A:The cash runway includes our core programs and clinical phases, but not all Phase 1 and Phase 2 trials are prior to potential cash out.
Q:What’s your latest strategy on collaboration?
A:We aim to focus on technology innovation and early development, while partnering for late-stage development in oncology.
Q:Can you give a sense of the timelines for the European Patent proceedings?
A:The next milestones include a hearing for the 775 patent on May 13-15, and if validity is confirmed, it will go to the infringement court on July 1st.
Q:Can you provide more detail on the Genmab collaboration that was terminated?
A:The collaboration was dormant for some time and did not lead to any significant outcomes, leading to a mutual agreement to terminate.
Q:What are you hoping to see in the Phase 1 data for the non-small cell program?
A:We want to see immune responses against the encoded antigen, and if we see clinical activity, that would be encouraging.
Q:How do you expect R&D costs to progress through 2025?
A:We aim for more cost efficiency and focus on our pipeline programs.
Q:Can you talk about the mRNA integrity data shown on Slide 13?
A:The data shows that mRNA integrity is still within specifications agreed with regulators after a year at room temperature.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the timeline for the first patient dose and the subsequent data readout, stating they want to be cautious and will provide updates as recruitment progresses. Additionally, there was a lack of clarity on the specific criteria for go/no-go decisions for GBM, with management providing general expectations without detailed metrics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EPO
GSK program
IND
LNP system
Phase study
UPEC
agreement GSK
antigen collaboration
cancer immunotherapy
cell lung
checkpoint inhibitor
condition
degree Celsius
degree Fahrenheit
glioblastoma study
infringement
licensing agreement
loss EUR
lung cancer
milestone payment
myNEO
oncology disease
outcome
patent form
patient cell
payment GSK
pembrolizumab
precision immunotherapy
program cell
program influenza
split
tail patent
tract
treatment
validity
CVAC Transcript
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript
Positive4-12
The earnings call indicates a significant improvement in financial performance, with a shift from operating losses to profits, and strong revenue growth due to a new partnership with GSK. Despite a slight EPS miss, the cash position is strong, and the company is strategically focusing on oncology. The Q&A section reveals cautious optimism in clinical trials and regulatory interactions, with no major negative surprises. Overall, the financial health and strategic focus on partnerships suggest a positive market reaction.
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Positive4-10
The earnings call highlights strong financial performance with a significant increase in full-year revenue due to a new GSK licensing agreement, a substantial upfront payment, and improved operating profit. The Q&A section indicates management's cautious optimism, and despite some vague responses, they reaffirm a strong cash position and financial runway. The strategic restructuring and workforce reduction pose some risks, but the overall sentiment is positive due to the financial improvements and strategic partnerships.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
Positive11-12
The earnings call highlights a strong financial performance, primarily due to a €400 million upfront payment from GSK, resulting in a significant revenue increase and a transition to operating profit. While there are concerns about litigation and R&D investment risks, the overall sentiment is positive due to strong cash position and promising business updates. The Q&A section did not reveal major negative surprises, and the optimistic guidance on oncology and infectious diseases further supports a positive outlook. The stock price is likely to react positively in the short term.
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
Unknown4-24
The earnings call reveals mixed signals: a strong cash position and increased Q4 revenue, but a full-year revenue decline and increased operating loss. The Q&A highlights uncertainties in vaccine timelines and oncology trials. Despite efficiency gains, cost management challenges persist. No guidance was provided, which typically concerns investors. Without a market cap, a neutral prediction is prudent, balancing positive cash flow extensions and strategic risks.
CVAC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
